Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
1(50.0%)
Phase 2
1(50.0%)
2Total
Early Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00440570Early Phase 1Completed

A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors

Role: lead

NCT00805337Unknown

Low Levels of Electromagnetic Fields to Treat Advanced Cancer

Role: lead

NCT00440934Phase 2Terminated

A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma

Role: lead

All 3 trials loaded